Clinical trial / 2020
High-dose omega-3 carboxylic acid did not reduce major adverse cardiovascular events compared with corn oil in high-risk patients.
A total of 13,078 statin-treated patients at high cardiovascular risk were randomized to receive 4 g/d of an omega-3 carboxylic acid formulation (EPA/DHA) or corn oil. The trial was prematurely halted for low probability of clinical benefit. The primary composite endpoint occurred in 12.0% of omega-3 CA patients versus 12.2% of corn oil patients (hazard ratio, 0.99 [95% CI, 0.90-1.09]; P = .84). A higher rate of gastrointestinal adverse events occurred in the omega-3 group (24.7%) compared to the corn oil group (14.7%).
- Study type
- Double-blind, randomized, multicenter trial
- Who was studied
- 13,078 statin-treated patients with high cardiovascular risk, hypertriglyceridemia, and low HDL-C
- What was measured
- Composite of cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina requiring hospitalization
THE PAPER
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Ridker PM, Ray KK, Katona BG, Himmelmann A, Loss LE, Rensfeldt M, Lundström T, Agrawal R, Menon V, Wolski K, Nissen SE. JAMA, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.